Life Sciences, Biotech & Pharma

How to get hired as a regulatory affairs specialist in 2026-27

Updated 5 October 2026 · 26 min read · by SkillSculptor

The short answer

Getting hired as a Regulatory Affairs Specialist in 2026-27 turns on nameable submission experience, not a licence: no government licenses regulatory affairs professionals, and the RAC credential from RAPS is voluntary and earned after the experience rather than as a route in. What a hiring manager screens for is whether you can say exactly which submission you worked on, in what role, to which agency or notified body, and what came back: an IND, a 510(k) built in eSTAR, a CBE-30 supplement, MDR technical documentation reviewed by a notified body, a clinical trial application in CTIS, a Module 2.7.4 summary you authored. People coming off the bench are hired fastest into regulatory CMC, where their specifications, stability protocols and method validation work is already Module 3 content; people coming from a research site, a clinic or a pharmacy are hired fastest into clinical regulatory and regulatory operations, where IRB submissions, consent versioning, Form FDA 1572s and safety reports are already the work. Interviews test three things: a reportability call handed to you cold, how you behaved under an agency clock, and whether you have ever refused the business a claim and kept the relationship. For pay, use employer ranges posted under state pay-transparency laws, the RAPS Scope of Practice and Compensation Report, and DOL H-1B disclosure data, because BLS publishes no wage series for this title: it sits inside OES 13-1041 Compliance Officers, which pools in unrelated compliance work and reads low.

Licence requiredNone. No government anywhere licenses regulatory affairs professionals. You can hold the title, author a submission and be the named company contact on a cover letter with no credential at all. The nearest thing to a defined qualification is EU MDR Article 15, which requires a device manufacturer to have a Person Responsible for Regulatory Compliance (PRRC) who holds a relevant degree in law, medicine, pharmacy, engineering or another relevant science plus at least one year in regulatory affairs or quality management systems, or four years of that experience without the degree. That is a named role inside a company, not a licence to practise, and micro and small enterprises may contract it in rather than employ it.
The credential: RACRegulatory Affairs Certification from RAPS (the Regulatory Affairs Professionals Society), offered as RAC Drugs and RAC Devices. It is a proctored exam, not a course, and eligibility combines degree level with years of regulatory work, so by design you qualify for it after you are already in the field. Check the current eligibility table on raps.org before paying: RAPS restructured the programme, and the old region-specific RAC (US), RAC (EU) and RAC (Canada) exams no longer exist, so a job ad or a mentor citing them is working from old information.
EducationA bachelor's degree in a life science, engineering, pharmacy or nursing is the practical floor for a specialist title. MS, PharmD and PhD are common and genuinely help in regulatory CMC and clinical regulatory, but none of them substitutes for a submission. Dedicated MS and graduate certificate programmes in regulatory affairs or regulatory science exist (Temple, Johns Hopkins, Northeastern and USC among others) and pay off mainly in two situations: your employer funds it, or you are switching in from a field with no regulated-industry story at all.
How long it takesAlready inside a regulated company: 6 to 18 months, and the route is almost always a documented internal move rather than an application. From outside, with no submission experience: 1 to 3 years, usually through an entry title (Regulatory Affairs Associate, Regulatory Operations or Publishing Specialist, Regulatory Coordinator, Labelling Associate) or a contract role at a CRO, a functional service provider or a regulatory consultancy. Passing the RAC does not shorten this clock. One named submission does.
What counts as submission experienceA specific submission, your specific role in it, the agency or notified body, and the outcome. Gap-assessing, compiling, publishing, authoring, reviewing, responding and owning are different claims, and hiring managers know the difference. The ones that move a resume: IND, NDA, BLA or ANDA content; a lifecycle change (prior approval supplement, CBE-30, CBE-0, annual report); a 510(k) in eSTAR, a De Novo or a PMA module; a Q-Submission or Pre-Sub; MDR or IVDR technical documentation that went to a notified body; a clinical trial application in CTIS; an EU variation; a Health Canada New Drug Submission or Medical Device Licence.
Typical hiring loopFour stages plus, very often, a written exercise: a recruiter screen, the hiring manager (usually a Manager, Senior Manager or Director of Regulatory Affairs), a cross-functional panel drawn from CMC or R&D, clinical operations, quality and pharmacovigilance, then a case or writing task. The exercise is the real filter. It is usually one of: make a reportability call on a change you are handed cold, triage an FDA Information Request or an Additional Information letter, or write half a page against a named module heading.
Where to check payBLS publishes no wage series for this job title. The occupation maps to O*NET 13-1041.07 Regulatory Affairs Specialists, which sits inside BLS OES 13-1041 Compliance Officers, a broad code that pools in unrelated compliance work and reads low for regulatory affairs. Three checkable sources are better: employer ranges posted under state pay-transparency laws (California, Colorado, Washington, New York, Illinois, Minnesota, Maryland, New Jersey, Massachusetts, Vermont and others); the RAPS Scope of Practice and Compensation Report, which segments by specialty, modality and seniority; and DOL H-1B labour condition application disclosure data, which lists actual offered salaries by job title, employer and work location for sponsoring companies.
Where the jobs areDrug and biologic hubs: Boston and Cambridge, the San Francisco Bay Area, San Diego, New Jersey, Philadelphia, Research Triangle, suburban Maryland, Indianapolis, Chicago, Seattle. Device and diagnostics clusters: Minneapolis and St Paul, Orange County, San Diego, the Bay Area, Salt Lake City, Warsaw Indiana, Memphis, and internationally Galway and Limerick in Ireland and the Swiss and southern German medtech belt. Plus three employer types people forget: CROs, functional service providers and regulatory consultancies; notified bodies (BSI, TUV SUD, TUV Rheinland, DEKRA, SGS); and FDA itself, which posts reviewer and Regulatory Health Project Manager roles on USAJOBS.

There is no licence. The gate is submission experience you can name

Most people arriving at this job expect it to work like nursing or law: an exam, a board, a licence number. It does not. There is no regulatory affairs licence in the United States, the European Union, the United Kingdom or Canada. Nobody will check a credential before letting you author a module of a marketing application. That sounds like good news and it is only half good news, because the thing that replaces the licence is harder to fake and harder to acquire from outside.

What replaces it is a chain of accountability. A submission leaves the building with a company's name on it and a named human on the application form: Form FDA 1571 for an IND, signed by the sponsor; Form FDA 356h for an NDA, BLA or ANDA; a named regulatory contact in a device submission, which for a 510(k) is now captured inside eSTAR rather than on the old Form FDA 3514 cover sheet. Years later an investigator can pull that file and ask who decided what, and on what basis. A hiring manager interviewing you is deciding whether to hand their company's filing to you, so the screening is a proxy for one question: has this person already been accountable for a document an agency read?

That cuts in both directions, and the second direction is the one candidates miss. No exam blocks you, which is why career changers get in. But no exam gets you in either, which is why candidates who spend a year and a fee on a credential before they have any submission experience often find the market has not moved for them at all. The RAC is a real credential with real value at the Senior Specialist and Manager level, where it reads as commitment to the profession and shows up as a preference in job ads. It is not a substitute for being able to say "I authored 2.3.P and responded to two of the three information requests on it."

The other thing candidates miss is that "experience with submissions" is not a claim. It is a category of claim, and regulatory people are trained to notice the difference between the levels. Say which one you did, in your resume and out loud in the interview. The honest lower rung beats an inflated higher one every time, because the inflated one collapses under one follow-up question.

One genuine exception to "no credential" is worth knowing because it appears in job ads. EU MDR Article 15 requires a device manufacturer to have at its disposal a Person Responsible for Regulatory Compliance, with a qualification route written into the Regulation: a relevant degree plus at least one year in regulatory affairs or quality management systems, or four years of that experience without the degree. Read Article 15 itself rather than a summary, because the exact wording of the two routes decides whether you qualify, and micro and small enterprises may have the PRRC permanently and continuously at their disposal under contract, which is why consultancies advertise it. PRRC on a resume is a strong signal for European device roles and means nothing for US drug roles.

If you have ever been the named point of contact in a cover letter, the person who signed a change control as the regulatory reviewer, or the person who picked up the phone to a project manager at an agency, lead with it. It is the single most convincing line available to a junior candidate, and most people who have done it bury it.

Which submissions count, and the pipeline they belong to

Regulatory affairs is not one job market. It is at least four, and they hire from different pools: drugs and biologics, medical devices, in vitro diagnostics, and combination products. A recruiter filling a device requisition will not read a drug CMC resume carefully, and the reverse is just as true. Before you do anything else, pick which market you are selling into, then name the modality and the region in the first six lines of your resume. "Regulatory affairs professional with submission experience" tells a recruiter nothing. "US and EU regulatory affairs for Class II devices and software: 510(k) and MDR technical documentation" tells them whether to call you.

On the drug and biologic side the pipeline runs: pre-IND meeting, IND under 21 CFR 312, protocol amendments and annual reports during development, end-of-phase-2 and pre-NDA or pre-BLA meetings, then the marketing application under 21 CFR 314 or 601 in eCTD format, then the long tail of lifecycle work where most specialists actually spend their careers. That lifecycle work is what employers are hungriest for and what candidates describe worst: supplements and variations, labelling updates, site and process changes, annual reporting, safety reporting, listing and registration, and promotional material review. If you can say "I handled 14 Type IB and two Type II variations across four markets last year," you are more employable than someone who watched one approval happen.

On the device side the pipeline runs: Q-Submission or Pre-Sub to agree the evidence with FDA before you generate it, IDE if you need a clinical study under 21 CFR 812, then 510(k), De Novo or PMA, then post-market work that is at least as large: adverse event reporting under 21 CFR 803, corrections and removals under 806, labelling, and the decision that defines device regulatory judgment, whether a change to a cleared device needs a new 510(k) at all. FDA's guidance on that decision, with its flowcharts, is the single document a device candidate should be able to walk through from memory. Know too that eSTAR is the required template for 510(k)s and that FDA has been extending it to other submission types on a published schedule, so check FDA's eSTAR page for the current required list; a candidate who has never opened eSTAR is visibly behind.

Learn the clocks, because every interview touches them and candidates get them wrong in a way that is immediately audible. FDA's MDUFA goal for a 510(k) is 90 FDA days, which is not 90 calendar days: the clock stops when FDA issues an Additional Information request and you go on hold, and a hold routinely adds months. FDA's goal for written feedback on a Pre-Sub is within 70 days. PDUFA goals for a new molecular entity are 10 months from the filing date for standard review and 6 months for priority, with filing itself about 60 days after submission. The EU centralised procedure runs on 210 active days with clock stops for your responses, and the clock stops are where the calendar really goes. Nobody expects you to quote these as trivia. They expect you to plan as though they are real, which means knowing that a response deadline you miss costs the programme a quarter.

Europe is a separate competence and it is where the shortage is. For devices and diagnostics, MDR 2017/745 and IVDR 2017/746 mean technical documentation assembled to the Annexes (older colleagues still call it the technical file, which is MDD-era language), reviewed by a notified body rather than a government agency, with clinical evaluation or performance evaluation, post-market surveillance plans, PSURs, UDI and EUDAMED registration. The transition dates have been extended more than once, most recently for IVDR, and the Commission has signalled a targeted revision of both Regulations, so treat any date you read in an article, including this one, as a prompt to open the current consolidated text on EUR-Lex. For medicinal products, Europe means the centralised, decentralised and mutual recognition procedures, the variations framework under Regulation 1234/2008 with its Type IA, IAIN, IB and II categories, and clinical trials through CTIS under Regulation 536/2014, which has been the single entry point since the transition of legacy trials completed at the start of 2025.

Two pieces of live 2026-27 context are worth carrying into an interview because they show you read past the job description. First, FDA's Quality Management System Regulation, which amended Part 820 to align with ISO 13485, had a compliance date of 2 February 2026, so device companies are in post-transition remediation right now and that is generating real requisitions for people who can read a quality system against a regulation. Second, the US user fee programmes, PDUFA VII and MDUFA V, run through the end of fiscal 2027, so reauthorisation is being negotiated now and both fee amounts and performance goals are in motion.

Getting in from the bench, the clinic, or quality

This is the question most people arrive with, and the answer is more specific than "network and get a certificate." Every one of these backgrounds already produces regulatory content. The move is not acquiring new knowledge first; it is renaming what you already have in the vocabulary a regulatory hiring manager screens on, and then getting one documented regulatory task on the record.

From the bench, aim at regulatory CMC, and aim there deliberately rather than at generalist roles. Regulatory CMC is persistently hard to staff, for the structural reason that it needs someone who understands manufacturing and analytics well enough to argue about them, and most people who understand that well stay in manufacturing or analytics. Your existing work is Module 3 content under another name: specifications and their justification, stability protocols and stability data, analytical method validation against ICH Q2(R2) and development under Q14, process validation and comparability, container closure and extractables and leachables, deviations and out-of-specification investigations, tech transfer, and change control under ICH Q12 thinking about established conditions. A bench scientist who can say "I wrote the stability protocol and the justification of specifications, and I have seen how a method change gets assessed for reportability" is a regulatory CMC candidate today.

From the clinic, the pharmacy or the research site, aim at clinical regulatory and regulatory operations. Study coordinators, research nurses, staff nurses on trial units and investigational pharmacists already handle the submissions: IRB and ethics committee packages, informed consent form versioning and the discipline of knowing which version was signed by which subject, Form FDA 1572 and investigator qualification, financial disclosure, protocol amendments, deviations, IND safety reporting timelines under 21 CFR 312.32, annual reporting under 312.33, DSURs, registration and results posting obligations, and inspection readiness including the trial master file. That is a regulatory CV already. Pharmacists have a second door other clinicians do not: labelling and promotional review, where knowing how a prescribing information document is actually used at the point of care is worth more than any training course.

From quality and manufacturing, aim at device regulatory and the quality-adjacent regulatory work. GMP QA people know CAPA, deviations, complaint handling, change control, supplier qualification and audit response, and after the QMSR compliance date in February 2026 the ability to read a quality system against both ISO 13485 and the US regulation is in demand. Device complaint handlers already make reportability decisions under 21 CFR 803, which is regulatory judgment, and most of them do not put it on a resume in those words.

Two more paths worth naming. Medical writers convert directly into the Module 2 summaries, 2.3, 2.5 and 2.7, which are the most senior-feeling writing in a submission. Clinical data managers and statistical programmers convert into the electronic data side of submissions, where the standards and conformance expectations are their existing job. Both are shorter hops than people expect.

You can learn the content for nothing, from the primary sources, which is also how you get past the detail probes in the interview. Read a full approval package on Drugs@FDA, including the correspondence and the information requests, and you will have seen what a review actually argues about. Read a 510(k) summary and a De Novo decision summary in FDA's device databases. Read an EPAR on the EMA site next to the consolidated MDR text on EUR-Lex. Work through CDRH Learn, which is free. Read untitled letters and warning letters as precedent rather than news. None of this is a credential and all of it is audible in an interview, because it is where the specific vocabulary comes from.

Whatever your origin, the highest-yield single action is the same, and it is not a course: do the regulatory work before you have the title, and get it documented. Volunteer for the gap assessment nobody wants. Ask to be the person who assembles the response to the notified body finding. Offer to maintain the labelling change log. Then get it into a written objective, a performance review, or an email from the regulatory lead saying what you did, because when you apply externally your evidence is your ability to describe it precisely, and when you apply internally the regulatory manager who watched you do it is the decision maker. Internal moves are how most regulatory affairs careers actually start. External applications from unrelated industries are how most of them stall.

Where you specialise, and which niches are short of people

Generalist "Regulatory Affairs Specialist" postings attract the most applicants and the widest range of backgrounds, which makes them the hardest doors in the field for a career changer. The niches attract fewer qualified applicants and are easier to enter from an adjacent technical background. Choosing one and saying so in your first line is a competitive act, not a limitation. Where this article says a niche is short of people, that is a claim about how hard employers find it to fill, not a promise about money: pay by specialty is segmented in the RAPS Scope of Practice and Compensation Report and visible in posted ranges, and those are the places to check it.

Regulatory CMC is the deepest shortage, for the boring structural reason given above. If you came off a bench, this is the obvious target. Labelling is the most underestimated: it looks clerical from outside and is the opposite, because every word in a prescribing information document is a regulated claim with a lineage, and a labelling specialist who loses track of a version creates a reportable problem.

Promotional and advertising review is its own discipline and the one that most tests the trait the rest of the job also needs. You sit in a review committee with commercial, medical and legal, and you decide whether a claim is substantiated, whether fair balance is adequate, and whether the piece can go out. You submit at first use on Form FDA 2253. You read untitled letters and warning letters not as news but as precedent about how far other companies got before being stopped. Commercial colleagues are paid to push. The job is to say no clearly, in writing, with a reason attached, and keep the relationship.

Devices and diagnostics are where the regulation has moved most in the last few years: MDR, IVDR, the QMSR alignment, premarket cybersecurity obligations for cyber devices under section 524B of the Federal Food, Drug, and Cosmetic Act with its software bill of materials and vulnerability management expectations, and AI-enabled device functions. IVDR in particular has absorbed an enormous amount of work with a limited pool of people who have actually assembled performance evaluation documentation. Combination products are the other persistent shortage: an autoinjector or a prefilled syringe is governed under 21 CFR Part 4, needs human factors work and a device constituent story, and sits across two regulatory cultures that do not naturally talk to each other. People who can bridge drug and device are rare enough that employers go looking for them.

Cell and gene therapy regulatory sits with CBER's Office of Therapeutic Products and rewards people who can hold a comparability and potency argument together across a process that changes while the product is in development. Regulatory operations, publishing and RIM administration is the quietest good door: it is a hirable technical skill, learnable in months rather than years, it gets you inside the submissions, and it is a credible route into strategy afterwards. Regulatory intelligence, where you track guidance, precedent and competitor approvals, suits people who read for a living and is difficult to enter cold but easy to grow into.

One warning about titles. "Regulatory Affairs Specialist" means very different jobs at different company sizes, and you must read the posting for which. At a 40-person biotech the specialist may be the entire regulatory function, reporting to a consultant, doing CMC, clinical and operations at once, with nobody to check their work. At a large pharmaceutical company the same title might mean you own variations for three markets and little else. Neither is better. They produce completely different next jobs, and an interviewer will respect you for asking which one you are looking at.

How the hiring actually runs

Your application lands in an enterprise applicant tracking system, usually Workday, iCIMS, SuccessFactors or Greenhouse, and the first read is a keyword read by a corporate or agency recruiter who is not a regulatory professional. They are checking four things and nothing subtle: submission types, modality, regions, and systems. If your resume says "prepared regulatory submissions for medical products" instead of "510(k), De Novo, MDR technical documentation, Class II and III devices, US and EU, Veeva Vault RIM," you will not reach the hiring manager, and the hiring manager will never know you existed. This is the single most common reason qualified career changers get no replies.

Agency recruiters matter more in regulatory affairs than in most functions, because there are specialist regulatory and quality search firms whose entire business is this field. They find you by the same keywords. Being findable, with an accurate and specific profile, generates inbound contact that the open market does not. Contract and functional service provider roles come through these firms first, and a six-month contract covering a leave is a genuinely good entry: it is a real submission, a real reference, and it often converts.

The hiring manager screen is where the job is really decided. It is usually 45 minutes with a Manager, Senior Manager or Director of Regulatory Affairs who has read your submission list and will test it. Expect them to pick one line and go three questions deep. This is also where you learn the shape of the role if you ask: how many submissions a year per person, whether publishing is in-house or outsourced, who signs, how a change control reaches regulatory, which RIM system, and what the last inspection or notified body audit found.

The panel is cross-functional by design, because the job is cross-functional. Expect some combination of CMC or R&D, clinical operations, quality, pharmacovigilance, and sometimes commercial or legal. They are not testing your regulatory knowledge; they are testing whether you can be worked with when you are the person saying no. The clinical operations interviewer wants to know whether you will block their timeline without explaining it. The quality interviewer wants to know whether you understand that their change control and your reportability assessment are the same decision from two angles. The commercial interviewer, if there is one, wants to know whether you can be reasoned with.

Then the exercise. Not every company runs one; the good ones do, and it is almost always one of three forms. A reportability case: here is a change, tell us how you would report it and why. A response triage: here is an information request or a deficiency letter, how do you sequence the answer and who do you pull in. A writing sample: half a page against a named section, or a redacted piece of your own work. If you are asked for your own writing, redact properly and say so, or better, hand over the gap assessment you built against public documents. Sending unredacted material from a previous employer is the fastest way to lose an offer in a field whose entire point is handling confidential information correctly.

Timelines vary more than in most functions. A 30-person biotech with a filing deadline can go from first contact to offer inside two weeks. A large pharmaceutical company can take three months and then freeze the requisition. Keep more than one process alive, and ask directly at the recruiter screen when they need someone in the seat, because the answer tells you how real the role is.

The resume: a submissions table, part numbers, and what gets ignored

A regulatory affairs resume has one structural feature that most candidates omit and that changes the outcome: a submissions table. Not prose about your responsibilities, a table. Columns for submission type, product or modality, region and agency, your role, and the outcome with a date. A hiring manager reads that table first and everything else second, because it answers their only real question in fifteen seconds. If you have done this work, the table makes you obviously hirable. If you have not, building the table honestly shows you exactly which claim you are entitled to make and which you are not, which is useful before an interview rather than during one.

Be exact about verbs and outcomes, including the unflattering ones. "510(k) cleared" is good. "510(k) received an Additional Information request on biocompatibility; I drafted the response; cleared four months later" is better, because it proves you were there when it was hard. Regulatory managers do not expect clean histories; they expect candidates who can describe a deficiency letter without flinching. The candidate who has only ever listed approvals reads as someone who watched.

Name part numbers and guidance by number, and only the ones you have actually used. 21 CFR 312 for INDs, 314 for NDAs and ANDAs, 601 for biologics, 820 as amended to the Quality Management System Regulation, 803 for device reporting, 806 for corrections and removals, 11 for electronic records, 50 and 56 for consent and IRBs, 210 and 211 for drug GMP, Part 4 for combination products. Add the ICH guidelines you have worked to rather than the ones you have heard of: M4 for the CTD, E6(R3) for GCP since its adoption at the start of 2025, Q2(R2) and Q14 for analytical validation and development, Q9(R1) for quality risk management, Q12 for lifecycle management. A list of regulations you merely read is obvious from across a room, and one follow-up question exposes it.

List systems, because they are a real screening filter and the cheapest gap to close. Veeva Vault RIM is the one named most often in postings, and Veeva publishes self-service training and runs an associate-level certification, so check the current catalogue, prerequisites and cost before you plan around it. Also name whichever of these you have used: LORENZ docuBridge, EXTEDO, Certara GlobalSubmit, MasterControl, TrackWise, the FDA Electronic Submissions Gateway, eSTAR, CTIS, EUDAMED, and intelligence tools such as Cortellis or Citeline. For a publishing or operations role these are not a nice-to-have, they are the job description.

Respect confidentiality and say that you are doing so. You can describe submission type, modality, phase, region, your role and the outcome without naming an unapproved product or disclosing a specific finding: "a Phase 3 oncology IND" and "a Class II orthopaedic implant" are safe, informative, and demonstrate judgment. An interviewer notices a candidate who handles this well, because it is a live preview of how you would handle their data. Never invent detail to fill the gap that confidentiality creates. Say what you cannot say.

What gets ignored or actively hurts: generic competency lines ("excellent attention to detail," "strong communicator") in a field where the resume itself is the attention-to-detail test; certifications from unrelated domains; a headline that says "regulatory professional" without naming drugs or devices; soft verbs ("supported," "was involved in," "assisted with") where a specific verb was available; and any typo or formatting inconsistency at all. The last one is not pedantry and it is not unfair. The job is producing documents an agency will read line by line, and your resume is the only writing sample they have before they decide whether to talk to you. Two pages is normal; three is acceptable after fifteen or more years, because at that point the submission list is the evidence.

The interview: pathway judgment, agency clocks, and saying no to the business

Regulatory interviews are less behavioural than most and closer to an oral examination with a judgment component. Four things are being tested, and you can prepare for all of them specifically.

First, pathway and reportability judgment, handed to you cold. The classic drug version: here is a change to a manufacturing process or a new fill-finish site, is it a prior approval supplement, a CBE-30, a CBE-0 or an annual report item? The classic device version: here is a change to a cleared device, does it need a new 510(k)? The answer they want is never a bare yes or no, and a confident bare answer is a worse performance than a thoughtful uncertain one. Answer in a fixed shape: what regulation or guidance governs this, what the risk is to safety or effectiveness and what the data says about it, what precedent exists, what my recommendation is, and what I would verify or ask the agency before committing. That shape is the job. Say it out loud and you are demonstrating the actual work rather than reciting an answer.

Second, agency and notified body interaction under a clock. Expect: tell me about a meeting you prepared for, and what you put in the briefing package. Tell me about an information request with a short deadline and how you handled it. Tell me about a time the agency disagreed with your position. Tell me about a finding, a 483 observation or a non-conformity and what you did in the following week. If you have never interacted with an agency, do not pretend; say what you have done instead, which is usually preparing content someone else sent, and say that you read the responses back. In 2026 it is also fair to say that after the 2025 reductions in force at FDA you plan submissions around formal interactions you can schedule rather than around informal feedback you hope to get. That observation lands well because it is operationally useful.

Third, and this decides more offers than anything technical: can you refuse the business and make it stick? Expect some version of "tell me about a time you told commercial, or a senior leader, that they could not do something." They are listening for three elements. That you said no clearly rather than hinting. That you gave a reason tied to a regulation or a risk, not to your authority. And that the relationship survived, usually because you came back with what they could do instead. Candidates who have no such story, or whose story is about being overruled and resenting it, do not get regulatory offers, because the entire value of the function is a person who holds a line politely under pressure from people more senior than them.

Fourth, small precise detail probes, used to check whether you really did the work. Which section holds drug product stability data. What goes in 2.7.4. The difference between Form 1571 and Form 1572 and who signs each. What a refuse-to-accept decision on a 510(k) is, how it differs from a refuse-to-file on an NDA, and what you do in the week after one. What a complete response letter is. Which EU variation type a minor labelling change falls into. What goes into a notified body's technical documentation versus what stays in your quality system. These are not trick questions. They take ten seconds to answer if you have done it and they are unanswerable if you have not, which is exactly why they are asked. Prepare them for the specific pathway on the job description rather than trying to cover everything.

Your own questions are part of the assessment, and in this field they are unusually revealing. Ask who signs submissions and who is the agency contact of record. Ask how a change control reaches regulatory and whether regulatory is a required approver. Ask what the last inspection or notified body audit found and what changed afterwards. Ask how many submissions a year the team does and whether publishing is in-house. Ask whether regulatory sits in the room when commercial builds a claim or reviews it afterwards. The answers tell you whether the function has real authority or is a rubber stamp with a job title, which is the thing you most need to know and the thing no job description says.

Pay, titles, contract work, and the 2026-27 market

Do not take a salary figure from any article, this one included. Take it from four checkable places. Employer-posted ranges under state pay-transparency laws, which are the most current data that exists because they are the actual range for the actual job. The RAPS Scope of Practice and Compensation Report, which is the field's own instrument and segments by specialty, modality, region and seniority. DOL H-1B labour condition application disclosure data, which lists offered salaries by job title, employer and work location for sponsoring companies and is unusually useful for benchmarking large pharmaceutical and device employers. And BLS, with a caveat: there is no BLS wage series for this title, the occupation maps to O*NET 13-1041.07 inside OES 13-1041 Compliance Officers, and that code pools in unrelated compliance work, so use it for employment trend rather than for pay.

Read titles sceptically, because they inflate and deflate by company size in opposite directions. At a small biotech, a Senior Manager may be the entire regulatory function reporting to a part-time consultant, with wide scope, no safety net and equity instead of cash. At a large pharmaceutical company, a Senior Specialist may own one market's variations with three layers of review above them, narrower scope and a much more orderly life. The ladder is roughly Associate, Specialist, Senior Specialist, Manager, Senior Manager, Associate Director, Director, and between those rungs the real variables are how many submissions you own, whether you are the agency contact, and whether you set strategy or execute it. In an interview, ask about those three rather than arguing about the title.

A large share of regulatory work is contract, and this is a structural feature of the field rather than a sign of a weak market. Companies staff peaks: a filing, a transition deadline, a remediation, a leave cover. That demand flows through CROs, functional service providers, specialist staffing firms and independent consultants. For a career changer this is good news, because contract hiring managers care about whether you can do the task in front of them, not about whether your last title matched. For experienced specialists, independent consulting is a common destination, usually built on one deep niche (IVDR technical documentation, combination products, CMC change assessments, publishing) rather than on general regulatory advice.

Remote work is more available here than in most life-science functions, because the artefacts are documents and the meetings are cross-functional calls. The exceptions are predictable: device regulatory sitting next to design and manufacturing tends to be onsite or strongly hybrid, anything touching label proofs or batch records tends to be onsite, and roles with a named site responsibility are onsite by definition. Expect hybrid as the default and read the posting rather than assuming.

On the market itself, be careful about anyone, including this article, who tells you the field is safe. What can be said without inventing data is the mechanism: most regulatory work is not discretionary. A company cannot defer its annual reports, its variations, its post-market reporting or its notified body deadlines because funding is tight, which is why the function is usually late to be cut and often backfilled on contract when it is. That is not immunity. Small-biotech funding cycles still produce layoffs with little warning, and a programme failure can remove a regulatory team overnight. Judge an individual employer by its pipeline and its runway, not by the sector.

Four live drivers of demand to know about and, where relevant, mention. Device companies passed the QMSR compliance date of 2 February 2026 and are in post-transition remediation. IVDR continues to absorb more documentation effort than the pool of people who have assembled performance evaluation documentation can supply, and the Commission has signalled a targeted revision of the device Regulations, which means more change management rather than less. The US user fee programmes, PDUFA VII and MDUFA V, expire at the end of fiscal 2027, so reauthorisation is being negotiated now and fee levels and performance goals are both in play. And FDA has been experimenting with compressed review clocks for a small number of selected products through the national priority voucher programme it introduced in 2025, which is worth understanding before you discuss timelines with a company that has one. A candidate who brings one of these up unprompted sounds like someone who already works in the field.

Working with AI in this role

What a regulatory affairs specialist has to know about AI in 2026-27

Start with the honest part, because overselling this in an interview costs you credibility with regulatory people specifically. At the core, this job has changed less than the hype suggests. The core of regulatory affairs is a defensible judgment, recorded, signed by a named human, and defensible to an investigator years later. Nothing available in 2026 lets you delegate a reportability decision, a submission signature or an agency commitment. There has been no visible collapse in demand for regulatory judgment, and the structural reason is simple: accountability cannot be automated, because accountability is the product.

Be precise about the thing people get wrong in both directions. It is not true that agencies reject model-based evidence: FDA has a published framework for it, and in-silico and statistical models have supported regulatory decisions for years. What no agency accepts is an unverified model output offered as the basis for a decision with nobody accountable for checking it. The question is never "did you use AI," it is "what was the model used for, how much of the decision rests on it, and what did you do to establish that it was credible for that use."

What has changed runs in two directions that candidates tend to conflate. The first is the tooling around the work: assembly, publishing checks, first drafts, translation, gap assessments and regulatory intelligence triage. The second is a whole new body of regulatory work created because the products themselves now contain AI, and because agencies have published explicit expectations for it. The second direction is where the hiring is, and it is the one most candidates are least prepared to discuss. Note also that there is rarely an "AI regulatory" job title: the work shows up as device regulatory with AI functions in scope, or CMC and clinical roles where modelling supports the evidence.

On the product side there is now a body of agency text to know by name. FDA finalised its guidance on predetermined change control plans for AI-enabled device software functions in December 2024, which is the mechanism that lets a model be updated after authorisation without a new submission for every change, provided you specified in advance what you would change and how you would validate it. FDA followed in January 2025 with draft guidance on using artificial intelligence to support regulatory decision-making for drug and biological products, built around defining a context of use and then establishing credibility proportionate to the risk the model carries in that context. EMA published a reflection paper on AI across the medicinal product lifecycle in 2024 and has an ongoing workplan with the national agencies. FDA also maintains a public list of authorised AI-enabled medical devices, which has grown past a thousand entries; open it and look at the current count, because it is the clearest single indicator of how much of this work exists.

Then there is the EU AI Act, Regulation (EU) 2024/1689, which is the part most device regulatory people are underprepared for. A device whose AI function requires notified body involvement is generally high-risk under the AI Act through the existing product legislation route, and that route's obligations were set to apply later than the general high-risk obligations (August 2027 rather than August 2026 as the Regulation was adopted). The Commission proposed changes to that timetable in late 2025, so check the current position before you quote a date. The practical consequence does not change with the dates: one technical documentation set answering two legal frameworks, assessed in one notified body conversation, on two different clocks. Anyone who can sequence that credibly is scarce, and saying so concretely in an interview is worth more than any claim of AI fluency.

On the tooling side, the constraint is data integrity and confidentiality, and the failure mode is specific: a hallucinated citation, a superseded guidance reference, a withdrawn or vacated rule cited as current law, or a number in a summary that does not trace back to the source document. Any of those inside a document an agency reads is a serious event, and in an inspection it is an integrity question rather than a typo. The working rule experienced people have settled on is unglamorous and correct: AI may draft, a human verifies against source, and the verification is part of the record. That means knowing what you are permitted to paste into which system, whether that system has been assessed, whether there is an audit trail, and who signed off that the output was checked. Agencies are doing the same thing on their side of the table, including the internal generative AI tool FDA rolled out to staff in 2025, which is worth knowing about because it tells you reviewers face the same verification question you do.

Be precise about what is actually being automated, because this is the question that separates a thoughtful answer from a slogan. Submission assembly, formatting, hyperlink and validation checks, first-pass gap assessments against a new guidance, translation and localisation, document comparison across versions, and the triage layer of regulatory intelligence: all of that has genuinely compressed. What has not moved is the reportability call, the strategy for a pathway, the negotiation with a reviewer, the signature, and the defence of a decision in an inspection. If anything, the automation has shifted the junior end of the job upward: fewer hours assembling, more hours judging, sooner than used to be the case.

Expect at least one AI question in any regulatory interview in 2026-27, from a company that may itself be unsure what it wants to hear. Answer it with a boundary in it. Say what you use AI for, say what you refuse to use it for and why, and then move to the product side, because that is where you can demonstrate you know the actual regulation rather than the discourse.

Knowing whether your own product contains a regulated AI function, and under which pathway

The first real question is classification, not technology. A model inside a device may be an AI-enabled device software function in its own right, a component of a larger device, or a development tool that never ships. Each lands in a different place, and in the EU a shipped AI function in a device that needs notified body involvement also pulls in the AI Act alongside MDR or IVDR. Candidates who talk about AI in the abstract while unable to say where it sits in a dossier do not sound like regulatory people.

Show it: Take a product you worked on, or a public example from FDA's AI-enabled device list, and say out loud where the AI function appears in the submission: which section describes the algorithm, what performance evidence supports it, what the labelling claims, how change control covers retraining, and whether there is a predetermined change control plan. If you have never had an AI function in scope, say that plainly and then describe how you would scope one.

Writing a predetermined change control plan an agency will accept

The PCCP is the mechanism that makes a learning product commercially viable, because without one every model update is a new submission. FDA's final guidance on PCCPs for AI-enabled device software functions came out in December 2024, so this is settled expectation rather than emerging practice. The content is specific: the modifications you intend to make, the protocol by which you will make and validate them including data management and performance evaluation, and an assessment of the impact of those modifications.

Show it: If you have drafted or reviewed one, name the three parts and say which was hardest to defend, which is nearly always the modification protocol, because it has to be specific enough to bound the change and general enough to be useful. If you have not, read the final guidance and be able to explain why a PCCP that says "we will retrain periodically to improve performance" is unacceptable.

Sequencing EU AI Act obligations against MDR or IVDR conformity

This is among the scarcest skills in device regulatory right now. A device whose AI function requires notified body involvement is generally high-risk under the AI Act via the existing product legislation route, whose obligations apply on a different date from the general high-risk obligations, and the Commission proposed moving that timetable in late 2025. So you are managing two frameworks with overlapping documentation and different deadlines through one notified body relationship, on dates that are still moving. Most teams have not worked out how their technical documentation, risk management file and post-market surveillance plan serve both.

Show it: Describe the overlap concretely: where the AI Act's risk management, data governance, logging, transparency and human oversight requirements map onto what MDR already demands, and where they genuinely add something. Saying "we treated it as one gap assessment against the existing technical documentation rather than a parallel project, and we re-checked the dates because they moved" shows you have thought about the practical problem.

The credibility-assessment habit for model-based evidence

FDA's January 2025 draft guidance on AI supporting regulatory decision-making for drugs and biologics is built on a pattern worth internalising well beyond AI: define the context of use, determine how much the decision rests on the model, then establish credibility proportionate to that. It is the same logic as quality risk management under ICH Q9 and the same logic that already governs PBPK and other in-silico evidence. Once you have the habit, every new modelling question becomes answerable.

Show it: Describe a model-based or statistical argument you had to defend and state the context of use explicitly: what decision it influenced, how much weight it carried, and what evidence you provided because of that weight. The phrase to avoid is "the model was validated," with no statement of what it was validated for.

Using an LLM on regulatory documents without creating a data-integrity finding

The tooling is useful and the boundaries are real. Unapproved product information, patient-level data, pre-decisional agency correspondence and trade-secret manufacturing detail do not belong in an unassessed consumer tool. Records that support a submission live under electronic records expectations, including audit trail and attribution, and "a model produced this and nobody checked it" is an integrity problem rather than a style problem.

Show it: State your own rule and the reason for it: which tool, on which content, with what verification recorded, and what you will not put in. If your employer has an approved tool with a vendor assessment behind it, say so; if it does not, say that you kept confidential content out of unapproved tools, which is the correct answer and sounds like someone who has thought about it.

Citation discipline: every reference traced to the primary text

Regulatory writing is dense with citations, and this is exactly where generated text fails, by producing plausible section numbers, guidance titles that do not exist, or rules that have since been superseded or struck down. The vacated FDA rule on laboratory developed tests is the live example of why you check: a 2024 rule, vacated by a federal court in 2025, still cited as current by people who read a summary rather than the docket. A wrong citation in a submission is a competence signal to a reviewer and a credibility loss you do not recover in that review cycle.

Show it: Describe your verification step concretely: every citation opened in the primary source, guidance checked against the current FDA or EMA page for withdrawal or revision, EU text read in the consolidated version on EUR-Lex because MDR and IVDR have been amended repeatedly. In an interview, correcting a date or status politely when you are confident is a positive, not a risk.

Structured content and RIM automation, because this is the part of your job being automated

The compression is happening in submission assembly, publishing, document comparison, labelling data reuse and product data management: Veeva Vault RIM and its peers, structured content authoring, IDMP data in Europe, structured product labeling in the US. The people who lose ground are the ones whose contribution was the manual assembly. The people who gain are the ones who configure, validate and own the data model, because somebody has to be accountable for whether the automated output is correct.

Show it: Name the system, name what you did in it beyond data entry (configuration, validation, migration, a data standard you cleaned up), and name one thing that went wrong with an automated step and how you caught it. That last detail marks you as the person who owns the output rather than the person who trusts it.

Being able to say plainly what AI has not changed

Regulatory hiring managers are professionally sceptical and they are measuring your calibration as much as your knowledge. A candidate who claims AI has transformed regulatory judgment sounds naive. A candidate who says the dossier standard, the named signature, the accountability and the inspection defence are unchanged, and then shows precisely where the tooling and the product requirements have moved, sounds like a colleague.

Show it: Prepare two sentences you believe: one on what you now do faster, with the verification step named, and one on what you would not delegate and why. The second sentence is the one that gets remembered, and it should be about accountability rather than about capability.

What a screen is looking for

These are the terms that a resume screen, human or automated, is matching against for this role. Use the ones that are true of you, in the words the posting uses.

Mistakes that cost people this job

Writing "experience with regulatory submissions" instead of naming the submissions, your role and the outcome. Recruiters screen on submission type, modality, region and system, and a resume without those words never reaches the regulatory hiring manager who would have recognised your background.

Build a submissions table with five columns: type, product or modality, region and agency, your role (gap-assessed, compiled, published, authored, reviewed, responded, owned), outcome and date. If the table is thin, that is information you need before the interview, not during it.

Paying for the RAC before you have any submission experience, in the belief that it is the entry credential. It is not an entry credential; eligibility is itself built on years of regulatory work, and it carries weight at Senior Specialist and Manager level where it reads as professional commitment.

Spend the months on getting one documented regulatory task inside your current employer, plus a systems line you can defend. Take the RAC once you are in and your employer is likely to fund it.

Applying only to postings titled "Regulatory Affairs Specialist." Those are the most contested doors in the field, and the generalist requisition is the one most likely to be filled by someone with directly matching experience.

Apply to the doors with fewer qualified applicants: Regulatory Operations or Publishing Specialist, Regulatory CMC Associate, Labelling Associate, Regulatory Coordinator, and contract roles at CROs, functional service providers and regulatory consultancies. Each one puts you inside real submissions, which is the thing the title does not give you.

Leading with scientific depth and burying the documentation evidence. Bench scientists moving into regulatory affairs often spend three quarters of the resume on assay development and one line on the stability protocol they wrote, which is the only line a regulatory CMC manager was looking for.

Invert it. Lead with the documents: specifications and their justification, stability protocols, method validation reports, change assessments, deviation investigations. Keep the science as the credential that lets you argue about those documents, not as the headline.

Mismatching region. A resume with only US drug experience applied to a global role whose real content is MDR technical documentation, or only European device experience applied to a US 510(k) role, reads as not having read the posting.

Name your regions explicitly in the headline and apply where they match. If you are deliberately crossing, say so in the first line of the cover note and name the specific transferable element, such as gap assessment method or publishing competence.

Over-claiming a level of involvement in the interview. Regulatory interviewers go three questions deep on one line, and the third question is where "I led the submission" collapses into "I formatted parts of it." In a field whose entire purpose is accurate representation, that collapse is disqualifying in a way it would not be elsewhere.

Claim the honest rung and make it vivid. "I compiled and published it, validated the sequence, and fixed the three hyperlink failures the day before the deadline" is a better interview moment than an inflated claim that breaks.

Answering a reportability question with a confident bare yes or no. The interviewer is not testing recall; they are testing whether you reason from the regulation and whether you know where the limits of your own judgment are.

Answer in the shape of the job: what governs this, what the risk is, what precedent exists, what I would recommend, and what I would verify or ask the agency before committing. Saying "I would want to see the comparability data before I committed" is strength, not weakness.

Treating a guidance document as if it were law, or treating law as if it were negotiable. Both errors are audible immediately. Guidance states nonbinding recommendations and a company may justify a different approach; a regulation does not work that way.

Say which is which when you cite something, and be able to explain the practical consequence: departing from guidance requires a documented justification you are prepared to defend, and departing from a regulation requires an approved exemption or nothing.

Having no story about refusing the business. Candidates who cannot describe telling commercial, clinical or a senior leader no, or whose only story is about being overruled, do not get regulatory offers, because holding that line politely is the function's reason for existing.

Prepare one real story with three parts: the clear refusal, the reason tied to a regulation or a risk rather than to your authority, and the alternative you came back with. If you were overruled above you, say what you documented and why documenting it mattered.

Citing a rule that is no longer current. The common 2026 examples are the vacated FDA rule on laboratory developed tests, retired region-specific RAC exams, superseded MDR and IVDR transition dates, Part 820 cited with no reference to the Quality Management System Regulation that amended it, and EU AI Act dates quoted from 2024 commentary.

Check the primary source before you cite it: the current FDA or EMA guidance page, the consolidated EU text on EUR-Lex, the RAPS eligibility table. A candidate who says "that rule was vacated in 2025, so the position is unsettled" gains more credibility in one sentence than a prepared answer gives in five.

Sending a previous employer's document as your writing sample, lightly redacted or not redacted at all. In a function whose entire premise is handling confidential information correctly, this ends the process, and interviewers have seen it often enough to look for it.

Build a sample you own: a gap assessment of a published 510(k) summary against a recognised standard, or a half-page module-style summary written from public data such as an approval package or an EPAR. Say what it is built from, which also shows you can read primary sources.

Quoting a salary band from an article or an aggregator in a negotiation. Pay in this field splits sharply by modality, specialty, company size and permanent versus contract, and the broad occupation code it is pooled into reads low.

Open posted ranges for the same title in the same state under pay-transparency laws, check the RAPS Scope of Practice and Compensation Report for your specialty and level, and look up the employer in DOL H-1B disclosure data if they sponsor. Quote a source, not a band.

Questions people ask

Do I need a licence or certification to work in regulatory affairs?

No. No jurisdiction licenses regulatory affairs professionals, and there is no mandatory certification in the United States, the European Union, the United Kingdom or Canada. You can hold the title of Regulatory Affairs Specialist, author submission content and be the named company contact with no credential at all. The RAC from RAPS (offered as RAC Drugs and RAC Devices) is voluntary, and its eligibility is itself based on years of regulatory work, so it is a mid-career signal rather than a way in. The closest thing to a defined qualification is the EU MDR Article 15 Person Responsible for Regulatory Compliance, a role inside a device manufacturer with an education-and-experience route written into the Regulation (a relevant degree plus at least one year in regulatory affairs or quality management systems, or four years without the degree), not a licence to practise.

How do I get into regulatory affairs with no submission experience?

Through a job that touches submissions rather than a job with regulatory in the title. The realistic entry points into regulatory affairs are Regulatory Affairs Associate, Regulatory Operations or Publishing Specialist, Regulatory Coordinator and Labelling Associate, plus contract roles at CROs, functional service providers and regulatory consultancies that staff filing peaks. The highest-yield single action, if you already work at a regulated company, is to do regulatory work before you have the title and get it documented: volunteer for the gap assessment, assemble the response to a notified body finding, maintain the labelling change log, then get it into a performance review. Most regulatory careers start as internal moves, and the regulatory manager who watched you do the work is the person who decides.

Is the RAC certification or a master's in regulatory affairs worth it?

Both are worth it at the right time, and neither substitutes for a submission. The RAC from RAPS carries weight at Senior Specialist and Manager level, appears as a preference in job ads and is often employer-funded, but its eligibility already requires years of regulatory work, so it will not get a career changer past a first screen; check the current eligibility table on raps.org, because RAPS restructured the programme to RAC Drugs and RAC Devices and the old RAC (US), RAC (EU) and RAC (Canada) exams no longer exist. A master's or graduate certificate in regulatory affairs or regulatory science pays off mainly when an employer funds it, when you are crossing from a field with no regulated-industry story, or when you want structured grounding in the regulations. If the choice is between a two-year degree and a six-month contract on a real filing, the contract moves your resume further, because the interview still opens with which submissions you have worked on.

Can I move into regulatory affairs from the lab bench?

Yes, and the right target is regulatory CMC specifically rather than generalist regulatory affairs. Regulatory CMC is persistently hard to staff because it needs someone who understands manufacturing and analytics well enough to argue about them, and a bench scientist's existing work is already Module 3 content: specifications and their justification, stability protocols and data, analytical method validation against ICH Q2(R2), process validation and comparability, container closure, deviations and out-of-specification investigations, change control. Invert your resume so the documents lead and the science supports them, because a regulatory CMC manager is reading for the stability protocol you authored, not the assay you developed.

Can a nurse, pharmacist or study coordinator move into regulatory affairs?

Yes, and the fastest routes into regulatory affairs are clinical regulatory and regulatory operations. Research nurses, study coordinators and site staff already produce regulatory artefacts: IRB and ethics submissions, informed consent versioning, Form FDA 1572 and investigator qualification, financial disclosure, protocol amendments, deviations, IND safety reporting timelines under 21 CFR 312.32, annual reports, trial registration and results posting, and inspection readiness including the trial master file. Pharmacists have a second door other clinicians do not, in labelling and promotional review, because understanding how prescribing information is used at the point of care is worth more there than any course. Describe those artefacts by name and you are already a credible clinical regulatory candidate.

Which submissions count most on a regulatory affairs resume?

The ones you can describe precisely, with your role and the outcome attached. For drugs and biologics: IND content, NDA, BLA or ANDA sections, and lifecycle work, meaning prior approval supplements, CBE-30 and CBE-0 changes, annual reports and EU variations by type. For devices: a 510(k) prepared in eSTAR, a De Novo, PMA modules, a Q-Submission or Pre-Sub, and MDR or IVDR technical documentation that went to a notified body. Combination products under 21 CFR Part 4, such as autoinjectors and prefilled syringes, are scarce experience because they need both regulatory cultures at once. Lifecycle volume is undervalued by candidates and highly valued by employers, because most specialist roles are throughput roles: "18 supplements and variations across five markets in 12 months" is stronger evidence than having watched one approval happen.

What do regulatory affairs interviews actually test?

Four things. Pathway and reportability judgment handed to you cold, such as whether a manufacturing change is a prior approval supplement, a CBE-30 or an annual report item, or whether a device change needs a new 510(k). Agency and notified body interaction under a clock, including meeting preparation, information requests, deficiency letters and findings. Whether you can refuse the business a claim and keep the relationship, which decides more offers than anything technical. And small precise detail probes used to verify you did the work, such as which section holds drug product stability data, what goes in 2.7.4, and who signs Form FDA 1571 versus Form FDA 1572. Many companies add a written exercise: a reportability case, triage of an information request, or half a page against a named section.

How much does a Regulatory Affairs Specialist earn?

Use sources rather than any quoted band, because pay varies sharply by modality, specialty, region, company size and whether you are permanent or contract. BLS publishes no wage series for this title: the occupation maps to O*NET 13-1041.07 Regulatory Affairs Specialists inside OES 13-1041 Compliance Officers, a broad code that pools in unrelated compliance work and reads low. Three sources are worth using: employer ranges posted under state pay-transparency laws, which are the most current data available because they are the actual range for the actual job; the RAPS Scope of Practice and Compensation Report, which segments by specialty, modality and seniority; and DOL H-1B labour condition application disclosure data, which lists offered salaries by title, employer and location for sponsoring companies.

Will AI reduce the number of regulatory affairs jobs?

Not at the judgment layer, because accountability is the product: a submission carries a company's name and a named human signature and must be defensible to an inspector years later, and no agency accepts an unverified model output as the basis for a reportability decision. What has genuinely compressed in regulatory affairs is submission assembly, publishing and validation checks, first-pass gap assessments, translation, document comparison and the triage layer of regulatory intelligence, which has pushed junior regulatory work upward toward judgment sooner than it used to happen. Meanwhile AI has created new regulatory work, because the products themselves now contain AI: predetermined change control plans for AI-enabled device software functions under FDA's December 2024 final guidance, credibility assessment for model-based evidence under FDA's January 2025 draft guidance for drugs and biologics, and EU AI Act obligations running alongside MDR or IVDR conformity.

What does a Regulatory Affairs Specialist do day to day?

Mostly three kinds of work. Producing and maintaining documents: authoring or reviewing submission sections, labelling, technical documentation, responses to agency questions, and the records that show why each decision was made. Making and defending reportability and pathway calls: a change arrives through change control, and you decide whether and how it is reported, then write down the reasoning. And coordinating across functions, since the content you own is generated by CMC, clinical, quality and pharmacovigilance, so much of the day is chasing, questioning and reconciling other people's material against a deadline. Scope varies enormously with company size: at a small biotech the specialist may be the entire regulatory function, while at a large pharmaceutical company the same title may own variations for a few markets with several layers of review above them.

Put this on a resume in about a minute

Paste your history once and point it at the Regulatory Affairs Specialist posting you are looking at. No account, no card.

Build my resume free More roles

Related roles